Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase EARLY_PHASE1 1

Status

Completed 39Recruiting 8Terminated 7Unknown 4Not yet recruiting 4Active not recruiting 4Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Carcinoma, Non-Small-Cell Lung 133Breast Neoplasms 95Colorectal Neoplasms 65Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Lung Neoplasms 44Triple Negative Breast Neoplasms 43Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Small Cell Lung Carcinoma 41Uterine Cervical Neoplasms 40Rectal Neoplasms 37Neoplasms 31Pancreatic Neoplasms 30Recurrence 29Neoplasm Metastasis 29Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Ovarian Neoplasms 23Nasopharyngeal Carcinoma 21Carcinoma, Renal Cell 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Endometrial Neoplasms 19Multiple Myeloma 18Head and Neck Neoplasms 18Biliary Tract Neoplasms 18

Interventions

Dexamethasone 2daratumumab 1belantamab mafodotin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Immunoglobulin Light-chain Amyloidosis × Clear all
NCT07524634 2026-04-24

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting
64 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Peking University People's Hospital

Phase 2 Not yet recruiting
39 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07055724 2025-07-09

Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis

Nanjing IASO Biotechnology Co., Ltd.

Phase 2 Not yet recruiting
17 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡